Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial

托珠单抗 医学 安慰剂 间质性肺病 内科学 不利影响 胃肠病学 随机对照试验 临床终点 外科 病理 疾病 替代医学
作者
Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Bridget K. Wagner,Mauro Zucchetto,Ganesh Raghu,Fernando J. Martínez,Jonathan Goldin,Jeffrey Siegel,Christopher P. Denton
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:205 (6): 674-684 被引量:90
标识
DOI:10.1164/rccm.202103-0714oc
摘要

Rationale: Tocilizumab, an anti-IL-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis (SSc)-associated interstitial lung disease (ILD) in a phase 3 randomized controlled trial. Objectives: Assess long-term safety and efficacy of tocilizumab. Methods: Adults with diffuse cutaneous SSc for ⩽60 months and elevated acute-phase reactants, including those with ILD, received weekly placebo or tocilizumab 162 mg subcutaneously in the 48-week, double-blind period and then open-label tocilizumab from Weeks 48 to 96 (placebo-tocilizumab; continuous-tocilizumab). Measurements and Main Results: Eighty-two of 107 patients in the placebo-tocilizumab group and 85 of 105 patients in the continuous-tocilizumab group completed 96 weeks. Mean age and disease duration were 48 years and 23 months; high-resolution computed tomography revealed ILD in 61%. Mean (95% confidence interval [CI]) change in modified Rodnan skin score from baseline to week 96 was -8.4 (-10.0 to -6.8) for placebo-tocilizumab and -9.6 (-10.9 to -8.4) for continuous-tocilizumab. Mean (95% CI) change in FVC (percent predicted) from baseline to week 96 was -3.3 (-5.1 to -1.5) for placebo-tocilizumab and -0.5 (-2.4 to 1.3) for continuous-tocilizumab among completers and, in a post hoc analysis, -4.1 (-6.7 to -1.6) and -0.6 (-3.1 to 2.0), respectively, among completers with ILD (mean [95% CI] change from Weeks 48 to 96: 0.9 [-0.8 to 2.7] and -0.4 [-2.3 to 1.5], respectively). Rates per 100 patient-years of serious adverse events from Weeks 48 to 96 were 14.8 for placebo-tocilizumab and 15.8 for continuous-tocilizumab. Conclusions: Tocilizumab preserved lung function, slowing decline in FVC, in patients with SSc, including those with ILD. Long-term safety was consistent with the known safety profile of tocilizumab. Clinical trial registered with www.clinicaltrials.gov (NCT02453256).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Distance发布了新的文献求助10
1秒前
2秒前
2秒前
专注灵凡完成签到,获得积分10
2秒前
Stageruner完成签到,获得积分10
2秒前
kiyo_v完成签到,获得积分10
2秒前
黄超超发布了新的文献求助10
3秒前
落寞剑成完成签到 ,获得积分10
3秒前
七子完成签到,获得积分10
3秒前
klio完成签到 ,获得积分10
4秒前
zzx396完成签到,获得积分0
5秒前
one完成签到 ,获得积分10
6秒前
十五完成签到,获得积分10
6秒前
ptjam完成签到 ,获得积分10
7秒前
神勇的晟睿完成签到 ,获得积分10
8秒前
8秒前
曾珍完成签到 ,获得积分10
8秒前
Muhi完成签到,获得积分10
8秒前
8秒前
自带蓝牙的土豆完成签到 ,获得积分10
9秒前
青羽落霞完成签到 ,获得积分10
10秒前
抹颜完成签到,获得积分10
11秒前
量子星尘发布了新的文献求助10
15秒前
胡图图完成签到,获得积分10
16秒前
睡觉大王完成签到 ,获得积分10
17秒前
18秒前
18秒前
19秒前
19秒前
24秒前
玩命的十三完成签到 ,获得积分10
24秒前
寂寞的诗云完成签到,获得积分10
26秒前
我爱科研完成签到 ,获得积分10
26秒前
27秒前
Bin_Liu发布了新的文献求助10
28秒前
She完成签到,获得积分10
28秒前
31秒前
Raki完成签到,获得积分10
32秒前
22完成签到 ,获得积分10
32秒前
Echo_1995完成签到,获得积分10
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022